CD19 and periventricular leukomalacia: Tocilizumab notably alleviated macrophage (CD68), B cell (CD19), T cell (CD3) and neutrophil (myeloperoxidase, MPO) infiltration, as well as gastric injury and mucosal apoptosis, in the tissues of PVL-treated mice (Fig. 2a, b).